

OIPF

AUG 06 2002

COPY OF PAPERS
ORIGINALLY FILEDSheet 1 of 1

FORM PTO 449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
IN01159K1SERIAL NO.:
10/052,386INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT:
SAKSENA, et alFILING DATE:
01/18/2002GROUP:
TBA

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA					
	AB					
	AC					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES	NO
<i>RM</i>	AD WO 01 74768	10/11/01	WIPO				
	AE WO 01 40262	06/07/01	WIPO				
	AF WO 00 52032	09/08/00	WIPO				
	AG WO 99 07734	02/18/99	WIPO				
	AH WO 98 17679	04/30/98	WIPO				
	AI						
	AJ						
	AK						
	AJ						
	AK						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>RM</i>	AL	WEI HAN, et al, "alpha-Ketoamides, alpha-ketoesters and alpha-diketones as HCV NS3 protease inhibitors", <i>BIOORGANIC & MEDICINAL CHEMISTRY LETTERS</i> , Vol. 10, No. 8, (2000), pp. 711-713.
<i>RM</i>	AM	LLINAS-BRUNET MONTSE, et al, "Studies on the c-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease", <i>BIOORGANIC & MEDICINAL CHEMISTRY LETTERS</i> , Vol. 8, No. 19, (1998), pp. 2719-2724.
	AN	
	AO	
	AP	
	AQ	

EXAMINER

DATE CONSIDERED

*RBM**1-27-04*

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/052,386
				Filing Date	January 18, 2002
				First Named Inventor	Saksena et al.
				Art Unit	1653
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	SCHERING 3.0-122 CIP

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
RLM	AA**	US-5,162,500	11-10-1992	Takeuchi et al.	
	AB**	US-5,359,138	10-25-1994	Takeuchi et al.	
	AC**	US-5,488,067	01-30-1996	Hanson	
	AD**	US-5,496,927	03-05-1996	Kolb et al.	
	AE**	US-5,514,694	05-07-1996	Powers et al.	
	AF**	US-5,633,388	05-27-1997	Diana et al.	
	AG**	US-5,739,002	04-14-1998	De Francesco et al.	
	AH**	US-5,763,576	06-09-1998	Powers	
	AI**	US-5,843,450	12-01-1998	Dawson et al.	
	AJ**	US-5,843,752	12-01-1998	Dasmahapatra et al.	
	AK**	US-5,849,866	12-15-1998	Kolb et al.	
	AL**	US-5,854,001	12-29-1998	Casey et al.	
	AM*	US-6,265,380-B1	07-24-2001	Tung et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number-Kind Code ² (if known)			
RLM	BA**	EP-0	423 358-A1	04-24-1991	Naganawa et al.	
	BB**	EP-0	672 648-A1	09-20-1995	Naganawa et al.	
	BC**	WO-02/18369-A2		03-07-2002	Babine et al.	
	BD**	CA-2362911-A1		09-08-2000	Takemura et al.	
	BE**	FR-2778406		11-12-1999	Hurst et al.	
	BF**	WO-92/11850		07-23-1992	Simpson et al.	
	BG**	WO-94/00095		01-06-1994	Eveleth et al.	
	BH**	WO-95/33764		12-14-1995	Charbonneau	
	BI**	WO-97/06804		02-27-1997	McDade	
	BJ**	WO-98/12308		03-26-1998	De Francesco et al.	
	BK**	WO-98/13462		04-02-1998	McIver et al.	
	BL**	WO-98/14181		04-09-1998	Chojkier et al.	
	BM*	WO-98/29435		07-09-1998	Baily et al.	
	BN**	WO-98/37180		08-27-1998	Chen et al.	
	BO**	WO-99/07733		02-18-1999	Llinas-Brunet et al.	
	BP**	WO-99/64442		12-16-1999	Matassa et al.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	RLM	Date Considered	1-27-04
--------------------	-----	-----------------	---------




PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/052,386
				Filing Date	January 18, 2002
				First Named Inventor	Saksena et al.
				Art Unit	1653
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	SCHERING 3.0-122 CIP

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
RSM	CA**	BARTENSCHLAGER et al., Substrate Determinants for Cleavage in cis and in trans by the Hepatitis C Virus NS3 Proteinase, Journal of Virology, Jan. 1995, Vol. 69, No. 1, pp. 198-205		
	CB**	BENNETT et al., The Identification of a-Ketoamides as Potent Inhibitors of Hepatitis C Virus NS3-4A Proteinase, Biorganic & Medicinal Chemistry Letters 11 (2001), pp. 355-357		
	CC**	BIANCHI et al., Synthetic Dipeptide Substrates for the Assay of Human Hepatitis C Virus Protease, Analytical Biochemistry 237, 239-244 (1996)		
	CD**	BOUFFARD et al., An in Vitro Assay for Hepatitis C Virus NS3 Serine Proteinase, Virology 209, 52-59 (1995)		
	CE**	CHO et al., Construction of hepatitis C-SIN virus recombinants with replicative dependency on hepatitis C virus serine protease activity, Journal of Virological Methods 65 (1997), 201-207		
	CF**	D'SOUZA et al., In vitro cleavage of hepatitis C virus polyprotein substrates by purified recombinant NS3 protease, Journal of General Virology (1995), 76, 1729-1736		
	CG**	FILOCAMO et al., Chimeric Sindbis Viruses Dependent on the NS3 Protease of Hepatitis C Virus, Journal of Virology, Feb. 1997, p. 1417-1427		
	CH**	HAHM et al., Generation of a Novel Poliovirus with a Requirement of Hepatitis C Virus Protease NS3 Activity, Virology 226, 318-326 (1996)		
	CI**	HAMATAKE et al., Establishment of an in vitro Assay to Characterize Hepatitis C Virus NS3-4A Protease Trans-Processing Activity, Intervirology 1996;39:249-258		
	CJ**	HARBESON et al., Stereospecific Synthesis of Peptidyl a-Keto Amides as Inhibitors of Calpain, J. Med. Chem. 1994, 37, 2918-2929		
	CK**	ITO et al., Cultivation of hepatitis C virus in primary hepatocyte culture from patients with chronic hepatitis C results in release of high titre infectious virus, J. Gen. Virol 1996 May; 77 (Pt 5):1043-54		
	CL**	LU et al., Poliovirus chimeras replicating under the translational control of genetic elements of hepatitis C virus reveal unusual properties of the internal ribosomal entry site of hepatitis C virus, Proc. Natl. Acad. Sci. USA, Vol. 93, pp. 1412-1417, February 1996		
	CM**	MIZUTANI et al., Characterization of Hepatitis C Virus Replication in Cloned Cells Obtained from a Human T-Cell Leukemia Virus Type 1-Infected Cell Line, MT-2, Journal of Virology, Oct. 1996, p. 7219-7223		
	CN**	MIZUTANI et al., Inhibition of Hepatitis C Virus Replication by Antisense Oligonucleotide in Culture Cells, Biochemical and Biophysical Research Communications, Vol. 212, No. 3, 1995, pp. 906-911		
	CO**	MIZUTANI et al., Long-Term Human T-Cell Culture System Supporting Hepatitis C Virus Replication, Biochemical and Biophysical Research Communications 227, 822-826 (1996)		
	CP**	NARJES et al., a-Ketoacids are Potent Slow Binding Inhibitors of the Hepatitis C Virus NS3 Protease, Biochemistry (2000), Vol. 39, pp. 1849-1861		
	CQ**	OGILVIE et al., Peptidomimetic Inhibitors of the Human Cytomegalovirus Protease, J. Med. Chem. 1997, 40, 4113-4135		
	CR**	SCARSELLI et al., GB Virus B and Hepatitis C Virus NS3 Serine Proteases Share Substrate Specificity, Journal of Virology, July 1997, p. 4985-4989		
	CS**	SCHECHTER et al., On the Size of the Active Site in Proteases, Biochemical and Biophysical Research Communications, Vol. 27, No. 2, 1967		
	CT**	SHIMIZU et al., Multicycle Infection of Hepatitis C Virus in Cell Culture and Inhibition by Alpha and Beta Interferons, Journal of Virology, Dec. 1994, p. 8406-8408		

Examiner Signature	RSM	Date Considered	1-27-04
--------------------	-----	-----------------	---------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known	
				Application Number	10/052,386
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	January 18, 2002
				First Named Inventor	Saksena et al.
				Art Unit	1653
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	SCHERING 3.0-122 CIP

CU**	STEINKUHLER et al., Product Inhibition of the Hepatitis C Virus NS3 Protease, Biochemistry 1998, Vol. 37, pp. 8899-8905
CV**	SUDO et al., Establishment of an in vitro assay system for screening hepatitis C virus protease inhibitors using high performance liquid chromatography, Antiviral Research 32 (1996), pp. 9-18
CW**	TAKESHITA et al., An Enzyme-Linked Immunosorbent Assay for Detecting Proteolytic Activity of Hepatitis C Virus Proteinase, Analytical Biochemistry (1997), 274, pp. 242-246
CX**	TALIANI et al., A Continuous Assay of Hepatitis C Virus Protease Based on Resonance Energy Transfer Dipeptide Substrates, Analytical Biochemistry 240 (1996), pp. 60-67
CY**	TAREMI et al., Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease, Protein Science (1998), 7:2143-2149
CZ**	TONG et al., Conserved mode of peptidomimetic inhibition and substrate recognition of human cytomegalovirus protease, Nature Structural Biology (1998), Vol 5., No. 9, pp. 819-826
CA1**	TSUDA et al., Poststatin, a New Inhibitor of Prolyl Endopeptidase, The Journal of Antibiotics (1996), Vol. 49, No. 3, pp. 287-291
CB1**	TSUDA et al., Poststatin, a New Inhibitor of Prolyl Endopeptidase, The Journal of Antibiotics (1996), Vol. 49, No. 9, pp. 890-899
CC1**	URBANI et al., Substrate Specificity of the Hepatitis C Virus Serine Protease NS3, Journal of Biological Chemistry (1997), April 4 Issue, pp. 9204-9209
CD1**	WANG et al., Expression of HCV NS3 Protease and Detection of Its Activity in Mammalian Cells, 4th International Meeting on Hepatitis C Virus and Related Viruses, Molecular Virology and Pathogenesis, March 6-10, 1997
CE1**	WASSERMAN et al., (Cyanomethylene) phosphoranes as Novel Carbonyl 1,1-Dipole Synthons: An Efficient Synthesis of α -Keto, Acids, Esters, and Amides, J. Org. Chem. (1994), Vol. 59, pp. 4364-4366.
CF1**	ZHANG et al., Probing the Substrate Specificity of Hepatitis C Virus NS3 Serine Protease by Using Synthetic Peptides, Journal of Virology, Aug. 1997, pp. 6208-6213

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	RBM	Date Considered	1-27-04
--------------------	-----	-----------------	---------